Research programme: inflammation therapeutics - Akari Therapeutics

Drug Profile

Research programme: inflammation therapeutics - Akari Therapeutics

Alternative Names: Bioengineered tick salivary proteins - Akari Therapeutics; CFX-1; MCF; MRX-5; OPRX; OPT 1; OPX-1; Orally absorbed C5 inhibitor - Akari Therapeutics; Tick derived anti-inflammatory compounds - Akari Therapeutics; Tick derived proteins - Akari Therapeutics; Tissue specific proteins - Akari Therapeutics

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Morria Biopharmaceuticals
  • Developer Akari Therapeutics
  • Class Anti-inflammatories; Antihistamines; Proteins
  • Mechanism of Action Arachidonic acid inhibitors; Complement system protein inhibitors; Inflammation mediator inhibitors; Leukotriene B4 inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation
  • No development reported Allergic conjunctivitis; Cystic fibrosis; Dry eyes; Eye disorders; Inflammatory bowel diseases

Most Recent Events

  • 04 Jan 2017 Preclinical trials of a C5 inhibitor in Inflammation in United Kingdom (PO)
  • 04 Jan 2017 Preclinical trials of tick derived proteins in Inflammation in United Kingdom (unspecified route)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-conjunctivitis in United Kingdom (Ophthalmic, Drops)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top